2-Methyl-6-Bromo Benzothiazole

2-Methyl-6-bromobenzothiazole (CAS 5304-15-4, molecular formula C₈H₆BrNS, molecular weight 228.11 g·mol⁻¹) is supplied as a crystalline solid with a melting range of 68–71 °C. The compound is manufactured under an ISO 9001:2015 quality management system and is typically offered in two specification grades—Research Grade (RG) and Technical Grade (TG)—that differ primarily in residual inorganic bromide content, trace-metal profiles, and chromatographic purity. For Research Grade material, purity by HPLC (USP <621>, area-normalization at 254 nm) is guaranteed at ≥99.0%, with individual unspecified impurities capped at ≤0.30%. Water content determined by coulometric Karl Fischer titration (ASTM E203-23) is held below 0.10%, and the bromide ion-level from incomplete ring-closure or debromination is controlled to ≤50 ppm. Technical Grade, intended for large-volume synthetic sequences where a downstream recrystallization or column fraction is already budgeted, allows an assay window of 97.0–99.0% and a water ceiling of 0.30%. The core heterocycle is a benzothiazole substituted with a methyl group at the 2-position and a bromine atom at the 6-position, creating an electron-deficient aryl bromide handle that participates in palladium-catalyzed cross-couplings (Suzuki–Miyaura, Buchwald–Hartwig, and Sonogashira reactions) with activation energies noticeably lower than those of the corresponding 6-chloro analog.

What Practical Constraints Arise From Residual Water in Palladium-Catalyzed Coupling Sequences?

Moisture ingress above 0.30% becomes operationally significant in anhydrous cross-coupling protocols where the active catalyst system—frequently Pd(PPh₃)₄ or a Pd(II) pre-catalyst paired with SPhos—exhibits decreased turnover rates in the presence of adventitious water, owing to competitive ligand hydrolysis and the generation of inactive μ-hydroxo-bridged palladium dimers. In kilogram-scale campaigns tracked via in-situ ReactIR, batch data from a production-scale vessel (glass-lined, 500 L) showed that when water content exceeded 0.25%, the induction period for Suzuki coupling with 4-fluorophenylboronic acid lengthened from 12 min to 41 min under otherwise identical conditions (toluene/EtOH, K₂CO₃, 80 °C). Consequently, for moisture-sensitive transformations, pre-drying of the benzothiazole substrate under vacuum (10 mbar, 45 °C, 16 h) to a water endpoint of ≤0.05% is recommended irrespective of the certificate-of-analysis value if ambient relative humidity during charge exceeds 60%.

Stability Under Thermal Stress and Light Exposure

Differential scanning calorimetry (DSC) traces at a ramp rate of 10 °C·min⁻¹ reveal a sharp endothermic melt at 68.8 °C (onset) with no exothermic decomposition observed below 280 °C, indicating a wide thermal processing window for melt-phase reactions. However, long-term isothermal hold experiments at 100 °C under air show detectable discoloration—attributed to radical-mediated bromine loss—after 8 h, with a Gardner color shift from 1 to 5. Photostability data per ICH Q1B Option 2 confirm that the solid is sensitive to UV-A irradiation: after 200 W·h·m⁻² exposure, HPLC purity drops by 0.8%–1.2%, with the primary degradant identified as debrominated 2-methylbenzothiazole. Storage in amber glass under nitrogen at 2–8 °C maintains specification purity for 24 months in real-time stability studies.

When the synthetic target contains acid-labile protecting groups, the trace acidity contributed by residual HBr or hydrolytic by-products can prematurely cleave Boc or tert-butyldimethylsilyl groups during coupling. In such cases, prior extraction of a dichloromethane solution of the bromobenzothiazole with saturated aqueous NaHCO₃ (2 × 0.5 vol) is employed to neutralize any adventitious acidity before solvent swap into the reaction medium. This procedure has been documented in the preparation of a p38 MAP kinase inhibitor intermediate where a Boc-piperazine moiety was retained only when the benzothiazole input carried a neutral pH extractables profile.

The particle size distribution of the crystalline powder influences dissolution kinetics in polar aprotic solvents such as DMF, NMP, and DMAc. Unmilled material typically exhibits a D₉₀ of 450–700 μm, requiring extended stir times at ambient temperature. For continuous-flow chemistry platforms employing packed-bed reactors or solid-dosing screw feeders with outer diameter 12 mm, the Technical Grade is offered in a micronized form (air-jet milled, D₉₀ ≤75 μm) to ensure consistent feed rates and avoid bridging. However, micronized lots show increased electrostatic charging at relative humidity below 30%, necessitating static-dissipative packaging (antistatic LDPE liners meeting EN 61340-5-1).

Where 6-Bromo Substitution Outperforms Other Halogenated Benzothiazoles in Medicinal Chemistry Scaffolds

Comparison with the 6-chloro analog (2-methyl-6-chlorobenzothiazole, CAS 2941-48-2) highlights a reactivity gradient rooted in the C–Br bond dissociation energy (337 kJ·mol⁻¹ versus 399 kJ·mol⁻¹ for C–Cl). In a model Suzuki coupling with phenylboronic acid catalyzed by Pd(dppf)Cl₂ (K₃PO₄, dioxane, 100 °C), the bromo derivative reaches >95% conversion within 2 h, whereas the chloro analog requires 12 h under identical conditions, per reaction calorimetry data from a ChemiSens CPA202 system. This kinetic advantage reduces palladium loading requirements—a critical cost driver—and minimizes protodehalogenation side products that complicate chromatographic purification. Additionally, 6-bromo substitution avoids the steric congestion of the 5-bromo isomer, which can retard oxidative addition due to peri-interactions with the sulfur atom, as evidenced by DFT calculations (B3LYP/6-31G*) reporting a 3.5 kcal·mol⁻¹ higher activation barrier for the 5-bromo congener.

Multiple pharmaceutical route scouting reports filed with regulatory agencies reference 2-methyl-6-bromobenzothiazole as a key building block in the synthesis of kinase inhibitors, particularly those targeting VEGFR-2 and c-Met. The bromine atom serves as a diversification point for late-stage introduction of substituted phenyl, pyridyl, or pyrimidyl rings. In one published process for a clinical candidate, the Suzuki coupling product was advanced without isolation directly to a Buchwald–Hartwig amination on the same benzothiazole core, demonstrating orthogonality of the bromide site with a triflate installed subsequently at the 4-position. Industrial campaigns typically observe a yield range of 85–92% for the initial coupling when the substrate is charged at 1.0–1.2 equivalents relative to the boronic acid, with mass balances exceeding 98% when coupling executes in THF/water mixtures containing 2 mol% Pd(OAc)₂ and PPh₃.

(a) Relative rate in Pd(0)-mediated coupling with phenylboronic acid under standard conditions. (b) Amino group requires protection in some cross-coupling regimes.

Supply chain specifications mandate that all lots intended for GMP intermediate production are accompanied by a transmissible impurity profile that quantifies previously unobserved synthesis-related substances such as 2-methylbenzothiazole (des-bromo impurity), 2,6-dibromobenzothiazole (over-brominated), and the 2-bromomethyl-6-bromo oxidation artifact. These by-products are resolved using an isocratic LC method with a C18 column (150 × 4.6 mm, 3.5 μm) and a mobile phase of acetonitrile:water (65:35 v/v) containing 0.1% trifluoroacetic acid; detection limits for each are established at 0.05% relative to the main peak. Manufacture under a state-of-the-art occupational exposure band (OEB 2) ensures airborne concentrations do not exceed 10 μg·m⁻³ during drumming and sampling operations in a contained isolator glovebox.

Regulatory pre-compliance documentation asserts that 2-methyl-6-bromobenzothiazole is manufactured in accordance with the European Union’s REACH Regulation (EC) 1907/2006 and is listed on the EINECS inventory with pre-registration completed for the 1–10 tonne per annum band. It is designated as a non-CMR substance, and reports from Ames II testing (OECD 471) show no mutagenic activity in Salmonella typhimurium strains TA98 and TA100 at concentrations up to 5000 μg per plate, with and without S9 metabolic activation. The SDS classifies it as a skin sensitizer category 1B based on the result of a local lymph node assay (OECD 429), with an EC3 value of 8.2%, requiring nitrile gloves tested to EN 374-3 with a breakthrough time exceeding 240 min.

In agrochemical intermediate schemes—specifically in the preparation of benzothiazole-containing succinate dehydrogenase inhibitors (SDHIs)—the 6-bromo substituent facilitates direct installation of a pyrazole-carboxamide pharmacophore via a tandem amination-carbonylation sequence. Process development reports from a pilot-plant campaign employing a 50 L Hastelloy reactor describe that careful control of the CO pressure at 5 bar and a temperature ramp from 60 to 90 °C suppresses the competing reductive debromination to <2%, a threshold that allows direct crystallization of the coupling product in 88% isolated yield with >99.5% HPLC purity. This tight operating window—±5 °C deviation from the ramp profile resulted in a yield drop of 7–10%—highlights the necessity for programmable logic-controlled jacket heating and in-line IR monitoring of CO uptake rates. The compound’s limited solubility in water (<0.1 g·L⁻¹ at 25 °C) and log P (experimentally determined shake-flask value of 3.2) facilitate extractive workup and phase-switch recovery strategies. When integrated into continuous flow sequences employing a Zaiput membrane separator, >99% of the unreacted benzothiazole can be recycled from the organic raffinate, reducing the effective process mass intensity by 22% relative to a batch equivalent. Because the 2-methyl group remains inert under the majority of cross-coupling and alkylation conditions, it serves as an internal reference for NMR quantification without interfering with downstream transformations.